Wolf

Important Investor Alert for All Owners of Quantum Corporation

Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Quantum Corporation (“Quantum” or the “Company”) (NYSE:QTM) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Quantum securities between May 10, 2016 and February 7, 2018 (“Class Period”), both dates inclusive. Investors who have incurred losses in shares of Quantum Corporation



IMPORTANT STEMLINE THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Securities Class Action Lawsuit Has Been Filed in the Southern District of New York Against Stemline Therapeutics, Inc.

NEW YORK, Feb. 07, 2017 — Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (NASDAQ:STML) on behalf of investors that acquired Stemline securities: (1) pursuant and/or traceable to Stemline’s secondary public …


Wolf Haldenstein Adler Freeman & Herz LLP and Monteverde & Associates PC Announces That They Have Filed a Lawsuit on Behalf of Shareholders of National Interstate Corp. In the Northern District of Ohio

Wolf Haldenstein Adler Freeman & Herz LLP and Monteverde & Associates PC announce that they have filed a class action lawsuit in the United States District Court for the Northern District of Ohio on behalf of all shareholders of National Interstate Corp. (“National Interstate”) ( NATL ) who owned shares of …


IMPORTANT LIPOCINE, INC. SHAREHOLDER ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Reminds Investors That a Class Action Lawsuit Has Been Commenced on Behalf of Shareholders of Lipocine, Inc.

Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of purchasers of Lipocine, Inc. (“Lipocine” or the “Company”) (LPCN) between June 30, 2015 and June 28, 2016, inclusive (the “Class Period”). Shareholders who have purchased …